Suppr超能文献

新型嵌合多激动剂肽(GEP44)以胰高血糖素样肽-1受体依赖的方式降低雄性和雌性饮食诱导肥胖小鼠的能量摄入和体重。

The Novel Chimeric Multi-Agonist Peptide (GEP44) Reduces Energy Intake and Body Weight in Male and Female Diet-Induced Obese Mice in a Glucagon-Like Peptide-1 Receptor-Dependent Manner.

作者信息

Blevins James E, Honeycutt Mackenzie K, Slattery Jared D, Goldberg Matvey, Rambousek June R, Tsui Edison, Dodson Andrew D, Shelton Kyra A, Salemeh Therese S, Elfers Clinton T, Chichura Kylie S, Ashlaw Emily F, Zraika Sakeneh, Doyle Robert P, Roth Christian L

出版信息

bioRxiv. 2024 May 21:2024.05.17.594690. doi: 10.1101/2024.05.17.594690.

Abstract

We recently reported that a novel chimeric peptide (GEP44) targeting both the glucagon-like peptide-1 receptor (GLP-1R) and neuropeptide Y1- and Y2 receptor (Y1R and Y2R) reduced energy intake and body weight (BW) in diet-induced obese (DIO) rats. We hypothesized that GEP44 reduces energy intake and BW primarily through a GLP-1R dependent mechanism. To test this hypothesis, GLP-1R mice and GLP-1R null (GLP-1R ) mice were fed a high fat diet for 4 months to elicit diet-induced obesity prior to undergoing a sequential 3-day vehicle period, 3-day drug treatment (5, 10, 20 or 50 nmol/kg; GEP44 vs the selective GLP-1R agonist, exendin-4) and a 3-day washout. Energy intake, BW, core temperature and activity were measured daily. GEP44 (10, 20 and 50 nmol/kg) reduced BW after 3-day treatment in DIO male GLP-1R mice by - 1.5±0.6, -1.3±0.4 and -1.9±0.4 grams, respectively ( <0.05), with similar effects being observed in female GLP-1R mice. These effects were absent in male and female DIO GLP-1R mice suggesting that GLP-1R signaling contributes to GEP44-elicited reduction of BW. Further, GEP44 decreased energy intake in both male and female DIO GLP-1R mice, but GEP44 appeared to produce more consistent effects across multiple doses in males. In GLP-1R mice, the effects of GEP44 on energy intake were only observed in males and not females, suggesting that GEP44 may reduce energy intake, in part, through a GLP-1R independent mechanism in males. In addition, GEP44 reduced core temperature and activity in both male and female GLP-1R mice suggesting that it may also reduce energy expenditure. Lastly, we show that GEP44 reduced fasting blood glucose in DIO male and female mice through GLP-1R. Together, these findings support the hypothesis that the chimeric peptide, GEP44, reduces energy intake, BW, core temperature, and glucose levels in male and female DIO mice primarily through a GLP-1R dependent mechanism.

摘要

我们最近报道,一种新型嵌合肽(GEP44)靶向胰高血糖素样肽-1受体(GLP-1R)以及神经肽Y1和Y2受体(Y1R和Y2R),可降低饮食诱导肥胖(DIO)大鼠的能量摄入和体重(BW)。我们推测GEP44主要通过GLP-1R依赖性机制降低能量摄入和体重。为验证这一假设,在给予高脂饮食4个月以诱发饮食诱导肥胖后,对野生型GLP-1R小鼠和GLP-1R基因敲除(GLP-1R-/-)小鼠进行为期3天的溶剂对照期、3天药物治疗(5、10、20或50 nmol/kg;GEP44与选择性GLP-1R激动剂艾塞那肽-4)以及3天洗脱期。每天测量能量摄入、体重、核心体温和活动量。GEP44(10、20和50 nmol/kg)在对DIO雄性GLP-1R+/-小鼠进行3天治疗后,体重分别降低了-1.5±0.6、-1.3±0.4和-1.9±0.4克(P<0.05),在雌性GLP-1R+/-小鼠中也观察到类似效果。在雄性和雌性DIO GLP-1R-/-小鼠中未观察到这些效应,这表明GLP-1R信号传导有助于GEP44引起的体重降低。此外,GEP44降低了雄性和雌性DIO GLP-1R+/-小鼠的能量摄入,但GEP44在雄性中不同剂量下似乎产生更一致的效果。在GLP-1R-/ -小鼠中,GEP44对能量摄入的影响仅在雄性中观察到,而在雌性中未观察到,这表明GEP44可能部分通过雄性中的GLP-1R非依赖性机制降低能量摄入。此外,GEP44降低了雄性和雌性GLP-IR+/-小鼠的核心体温和活动量,表明它也可能降低能量消耗。最后,我们表明GEP44通过GLP-1R降低了DIO雄性和雌性小鼠的空腹血糖。总之,这些发现支持了以下假设:嵌合肽GEP44主要通过GLP-1R依赖性机制降低雄性和雌性DIO小鼠的能量摄入、体重、核心体温和血糖水平。

相似文献

5
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mol Metab. 2019 Feb;20:51-62. doi: 10.1016/j.molmet.2018.12.001. Epub 2018 Dec 5.
6
Novel role of GLP-1 receptor signaling in energy expenditure during chronic high fat diet feeding in rats.
Physiol Behav. 2018 Aug 1;192:194-199. doi: 10.1016/j.physbeh.2018.03.037. Epub 2018 Apr 11.
8
A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats.
Neuropharmacology. 2021 Jul 1;192:108599. doi: 10.1016/j.neuropharm.2021.108599. Epub 2021 May 11.
9
Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y receptor triple agonist.
Eur J Med Chem. 2023 Feb 5;247:115036. doi: 10.1016/j.ejmech.2022.115036. Epub 2022 Dec 21.
10
The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
Diabetes Obes Metab. 2024 Jun;26(6):2368-2378. doi: 10.1111/dom.15551. Epub 2024 Apr 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验